Payment overview · 2025
General Payments
$1,804.90
93 reported records · 15 companies
Healthcare provider profile · identity verified
Samuel Jerome King, M. D.
Allopathic & Osteopathic Physicians|Family Medicine · PIKEVILLE, KY · NPI 1174550867
Verified facts
What the public records show
CMS Open Payments records show Samuel Jerome King, M. D. received $1,804.90 in general payments during 2025 across 93 reported records.
Abbott Laboratories accounted for 13.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Brilinta, Creon, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 183 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $241.32 | 13.4% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $234.38 | 13.0% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $228.43 | 12.7% | 18 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $194.08 | 10.8% | 15 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $168.06 | 9.3% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.17 | 7.9% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $114.60 | 6.3% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $111.85 | 6.2% | 4 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $110.59 | 6.1% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $105.69 | 5.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $85.97 | 4.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.36 | 1.1% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $16.46 | 0.9% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $16.38 | 0.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $14.56 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,804.90 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $321.94 | 21 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $241.32 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $185.51 | 4 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $168.06 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $159.71 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $151.51 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $111.85 | 4 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $105.69 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.76 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $94.28 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $76.92 | 10 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $76.92 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $68.07 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $52.44 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.19 | 2 | 2025 |
Source payment records
|
|||||
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $28.02 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BRILINTA brilinta |
2025 | Brilinta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 183 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 244 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 182 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 325 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 154 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
182 | 37 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
190 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
183 | 38 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
154 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
325 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1485 | 269 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1483 | 271 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1309 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 1119 | 214 |
| Potassium Chloride | Potassium Chloride | 939 | 201 |
| Lisinopril | Lisinopril | 859 | 166 |
| Tamsulosin Hcl | Tamsulosin Hcl | 723 | 123 |
| Ezetimibe | Ezetimibe | 661 | 120 |
| Furosemide | Furosemide | 616 | 142 |
| Simvastatin | Simvastatin | 567 | 118 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 559 | 121 |
| Dexamethasone | Dexamethasone | 557 | 357 |
| Irbesartan | Irbesartan | 549 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 538 | 111 |
| Metformin Hcl | Metformin Hcl | 537 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 533 | 93 |
| Gabapentin | Gabapentin | 511 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 508 | 92 |
| Trazodone Hcl | Trazodone Hcl | 445 | 96 |
| Omeprazole | Omeprazole | 425 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 397 | 86 |
| Losartan Potassium | Losartan Potassium | 386 | 78 |
| Tizanidine Hcl | Tizanidine Hcl | 386 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 381 | 76 |
| Sertraline Hcl | Sertraline Hcl | 378 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 359 | 97 |
| Azithromycin | Azithromycin | 350 | 261 |
| Meloxicam | Meloxicam | 330 | 77 |
| Mounjaro | Tirzepatide | 325 | 46 |
| Allopurinol | Allopurinol | 292 | 50 |
| Eliquis | Apixaban | 292 | 53 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 266 | 54 |
| Carvedilol | Carvedilol | 263 | 55 |
| Methylprednisolone | Methylprednisolone | 250 | 177 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 52 |
| Jardiance | Empagliflozin | 244 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 238 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 233 | 54 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 230 | 42 |
| Glyburide | Glyburide | 228 | 34 |
| Montelukast Sodium | Montelukast Sodium | 221 | 47 |
| Glipizide | Glipizide | 214 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 209 | 39 |
| Testosterone Cypionate | Testosterone Cypionate | 203 | 33 |
| Atenolol | Atenolol | 198 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 192 | 58 |
| Doxepin Hcl | Doxepin Hcl | 190 | 33 |
| Synthroid | Levothyroxine Sodium | 190 | 40 |
| Pregabalin | Pregabalin | 189 | 37 |
| Finasteride | Finasteride | 184 | 38 |
| Farxiga | Dapagliflozin Propanediol | 183 | 38 |
| Linzess | Linaclotide | 182 | 37 |
| Ibuprofen | Ibuprofen | 179 | 68 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 178 | 132 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 174 | 39 |
| Diclofenac Sodium | Diclofenac Sodium | 166 | 37 |
| Fluconazole | Fluconazole | 166 | 106 |
| Cephalexin | Cephalexin | 157 | 116 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 154 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 32 |
| Ondansetron Odt | Ondansetron | 149 | 71 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 149 | 33 |
| Famotidine | Famotidine | 148 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 146 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 146 | 61 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 144 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 142 | 29 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 136 | 22 |
| Valsartan | Valsartan | 133 | 25 |
| Celecoxib | Celecoxib | 131 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 131 | 97 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 128 | 25 |
| Chlorthalidone | Chlorthalidone | 127 | 29 |
| Sucralfate | Sucralfate | 124 | 35 |
| Prednisone | Prednisone | 122 | 32 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 121 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 120 | 26 |
| Donepezil Hcl | Donepezil Hcl | 120 | 21 |
| Spironolactone | Spironolactone | 115 | 21 |
| Alendronate Sodium | Alendronate Sodium | 114 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 109 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 19 |
| Ozempic | Semaglutide | 103 | 20 |
| Torsemide | Torsemide | 103 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 95 | 43 |
| Diltiazem 24hr Er | Diltiazem Hcl | 95 | 21 |
| Trulicity | Dulaglutide | 94 | 16 |
| Buspirone Hcl | Buspirone Hcl | 93 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 91 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 88 | 19 |
| Lansoprazole | Lansoprazole | 86 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 84 | 18 |
| Metformin Hcl Er | Metformin Hcl | 83 | 13 |
| Bupropion Xl | Bupropion Hcl | 82 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 11 |
| Baclofen | Baclofen | 79 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 79 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | 14 |
| Glimepiride | Glimepiride | 78 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 74 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 73 | 13 |
| Estradiol | Estradiol | 71 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 70 | 16 |
| Levetiracetam | Levetiracetam | 67 | 13 |
| Meclizine Hcl | Meclizine Hcl | 67 | 23 |
| Mupirocin | Mupirocin | 67 | 39 |
| Methocarbamol | Methocarbamol | 64 | 19 |
| Bumetanide | Bumetanide | 62 | 19 |
| Levofloxacin | Levofloxacin | 61 | 43 |
| Xarelto | Rivaroxaban | 61 | suppressed |
| Entresto | Sacubitril/Valsartan | 59 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 58 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 13 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 57 | 18 |
| Megestrol Acetate | Megestrol Acetate | 55 | 19 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 55 | suppressed |
| Ibu | Ibuprofen | 54 | 15 |
| Memantine Hcl | Memantine Hcl | 53 | 11 |
| Primidone | Primidone | 52 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 35 |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | 11 |
| Nadolol | Nadolol | 49 | suppressed |
| Nifedipine Er | Nifedipine | 49 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 11 |
| Amoxicillin | Amoxicillin | 48 | 37 |
| Glipizide Er | Glipizide | 48 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | suppressed |
| Topiramate | Topiramate | 48 | suppressed |
| Novolog Flexpen | Insulin Aspart | 47 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 13 |
| Fenofibrate | Fenofibrate,micronized | 45 | suppressed |
| Hydrocortisone | Hydrocortisone | 44 | 19 |
| Nitroglycerin | Nitroglycerin | 43 | 23 |
| Clonidine Hcl | Clonidine Hcl | 42 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 15 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 39 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Ranolazine Er | Ranolazine | 37 | suppressed |
| Eszopiclone | Eszopiclone | 36 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 35 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 33 | suppressed |
| Dutasteride | Dutasteride | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Sulfasalazine | Sulfasalazine | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Nystatin | Nystatin | 32 | 23 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | suppressed |
| Metronidazole | Metronidazole | 31 | 26 |
| Naproxen | Naproxen | 31 | 11 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 13 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 30 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Sotalol | Sotalol Hcl | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 11 |
| Colchicine | Colchicine | 26 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Novolog | Insulin Aspart | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Cilostazol | Cilostazol | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 16 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 21 | 16 |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Leflunomide | Leflunomide | 19 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 19 | suppressed |
| Desloratadine | Desloratadine | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Famciclovir | Famciclovir | 17 | 13 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | 13 |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Hailey Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Androgel | Testosterone | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Cymbalta | Duloxetine Hcl | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Provigil | Modafinil | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,804.90 · 93 records | Abbott Laboratories | AIRSUPRA, AREXVY, Auvelity, BRILINTA, CREON, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, JYNARQUE, Korlym, LINZESS, MOUNJARO, Ohtuvayre, Ozempic, Prolastin-C Liquid, QULIPTA, Rybelsus, SHINGRIX, TARPEYO, TRELEGY ELLIPTA, UBRELVY, Wegovy | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Brilinta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error